Amylin Pharmaceuticals, Inc. Uniquely Positioned to Build a Franchise in Metabolic Diseases
Two late-stage, first-in-class diabetes drug candidates
- SYMLIN™ (pramlintide acetate)
- Type 1 and insulin-using type 2 diabetes
- NDA amendment planned for submission in 1H 2003
-
- AC2993 (exenatide)
- Type 2 diabetes
- Global collaboration with Lilly
- Phase 3 AMIGO trials enrolled
- NDA submission planned for 2004
- AC2993 LAR - Phase 2 sustained-release program
Building on our strengths
- Cardiovascular – GLP-1, AC3056
- Obesity – AC162352 (PYY [3-36])
Improving the Lives of People with Metabolic Diseases